Ziconotide - A novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain - A short review

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 10, 2006, Pages 478-483

  Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Analgesia; Intractable pain; Intrathecal administration; N type calcium channel blocker; Ziconotide

Indexed keywords

ANALGESIC AGENT; FISH VENOM; MORPHINE; NARCOTIC ANALGESIC AGENT; OMEGA CONOTOXIN MVIIA; PLACEBO; VOLTAGE GATED CALCIUM CHANNEL;

ANALGESIC ACTIVITY; ANTINOCICEPTION; BLOOD DISEASE; BLURRED VISION; CANCER PAIN; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG CROSS TOLERANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENTIATION; DRUG TOLERABILITY; GAIT DISORDER; HUMAN; HYDROPHILICITY; HYPOTENSION; INTRACTABLE PAIN; KIDNEY DISEASE; LIVER DISEASE; LONG TERM CARE; MEMORY DISORDER; MENINGITIS; METABOLIC DISORDER; MUSCLE DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; NYSTAGMUS; OPIATE ADDICTION; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; RESPIRATION DEPRESSION; RISK REDUCTION; SHORT SURVEY; VISUAL ANALOG SCALE; VOMITING;

EID: 33749645832     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44478     Document Type: Short Survey

References (20)

1. Atanassoff PG, Hartmannsgruber MWB, Thasher J et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med. 2000; 25: 274-278.
2. Burger PJ, Kugler AR, Olson SC. A randomized, double-blind, placebo-controlled, rising dose, safety and tolerability study of CI-1009 (SNX-111) in healthy male volunteers. Internal Elan Study. 1996; 93-001, RR764-02622.
3. Doggrell SA. Intrathecal ziconotide for refractory pain. Expert Opin Invest Drugs. 2004; 13: 875-877.
4. Fisher R, Hassenbusch S, Krames et al. A consensus statement regarding the present suggested titration for Prialt (ziconotide). Neuromodul. 2005; 8: 153-154.
5. Hassenbusch SJ, Portenoy RK, Cousins M et al. Poly-analgesic consensus conference 2003: an update on the management of pain by intraspinal drug delivery - report of an expert panel. J Pain Sympt Managem. 2004; 27: 540-563.
6. Lyseng-Williamson KA, Perry C. Ziconotide. CNS Drugs. 2006; 20: 331-341.
7. Mathur JG. Ziconotide: a new pharmacological class of drug for the management of pain. Sem Anesth Perioperat Med Pain. 2000; 19: 67-75.
8. McGivern JG. Targeting N-type and T-type calcium channels for the treatment of pain. Drug Discovery Today. 2006; 11: 245-253.
9. McGuire D, Bowersox S, Fellmann JD et al. Sympatholysis after neuron specific, N-type, voltage sensitive calcium channel blockade: first demonstration of N-channel function in humans. J Cardiovasc Pharmacol. 1997; 30: 400-403.
10. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004; 11: 3029-3040.
11. Penn RD, Paice JA. Adverse effects associated with the intrathecal administration of ziconotide. Pain. 2000; 85: 291-296.
12. Rauck RL, Wallace MS, Leong MS et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Managem. 2006; 31: 393-406.
13. Staats PS, Yearwood T, Charapate AG et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. A randomized controlled trial. JAMA. 2004; 291: 63-70.
14. Stix G. A toxin against pain. Scient Amer. 2005; 292: 70-75.
15. Summary of product characteristics (SmPC). Ziconotide. European Medicines Evaluation Agency [online]. Available from URL: http//www.emea.eu.int (assessed May 31, 2006).
16. Thompson JC, Dunbar E, Laye RR. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician. 2006; 9: 147-152.
17. Wallace MS, Charapata SG, Fisher R et al. Intrathecal ziconotide in the treatment of chronic non-malignant pain: A randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006; 9: 75-86.
18. Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacother. 2005; 25: 1084-1094.
19. Wermeling DP, Berger JR. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacother. 2006; 26: 395-402.
20. Wermeling DP, Drass M, Ellis D et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003; 43: 624-636.